Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| MOTS-c | TB-500 (Thymosin Beta-4) | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 5-10 mg administered 3-5 times per week via subcutaneous injection. | Research indicates 2-2.5 mg administered twice weekly via subcutaneous injection. |
| Timing | Morning administration preferred. Can be dosed pre-workout for enhanced exercise performance. | No strict timing requirements. Can be administered at any time of day. Systemic action means injection location is not critical. |
| Cycle Duration | 8-16 week cycles. | Loading phase: 4-6 weeks. Total cycle: 8-16 weeks. |
| Evidence Level | Emerging (strong preclinical) | animal_plus_anecdotal |
MOTS-c is a 16-amino acid mitochondrial-derived peptide encoded by the 12S rRNA gene of the mitochondrial genome. It primarily acts through the folate-AICAR-AMPK pathway: by regulating the folate cycle and de novo purine biosynthesis, it increases AICAR accumulation, which phosphorylates and activates AMPK. This enhances glucose uptake in skeletal muscle, improves insulin sensitivity, and mimics exercise-mediated physiological responses. Skeletal muscle MOTS-c levels increase 11.9-fold in response to acute exercise in young men.
Research indicates 5-10 mg administered 3-5 times per week via subcutaneous injection.
Morning administration preferred. Can be dosed pre-workout for enhanced exercise performance.
8-16 week cycles.
TB-500 is a synthetic fragment of Thymosin Beta-4, a 43-amino acid protein that sequesters G-actin monomers, preventing premature polymerization and facilitating cellular migration and morphological changes essential for wound healing. It upregulates actin to promote cell migration, proliferation, and differentiation of stem/progenitor cells at injury sites. TB-500 also enhances angiogenesis, reduces inflammation, and promotes tissue remodeling through increased re-epithelialization and vascular density.
Research indicates 2-2.5 mg administered twice weekly via subcutaneous injection.
No strict timing requirements. Can be administered at any time of day. Systemic action means injection location is not critical.
Loading phase: 4-6 weeks. Total cycle: 8-16 weeks.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →